Evidence map›Paper›PMID 37634292›Full record

ArticleVirology2023

Creation and characterization of a recombinant mammalian orthoreovirus expressing σ1 fusion proteins encoding human epidermal growth factor receptor 2 peptides.

Nicole A Jandick, Cathy L Miller

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicole A JandickMolecular, Cellular, and Developmental Biology Interdepartmental Program, Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, 50011, USA.
Cathy L MillerMolecular, Cellular, and Developmental Biology Interdepartmental Program, Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, 50011, USA. Electronic address: clm@iastate.edu.
Iowa State University · US

Funding

Oncolytic reovirus modulation of the cancer cell hypoxic responseR15CA202984 · NCI · IOWA STATE UNIVERSITY · PI MILLER, CATHY L · 2017 to 2017
$441k
NCI NIH HHS R15 CA202984
6 · The paper itself

Abstract

Mammalian orthoreovirus (MRV) is an oncolytic virus that has been tested in over 30 clinical trials. Increased clinical success has been achieved when MRV is used in combination with other onco-immunotherapies. This has led the field to explore the creation of recombinant MRVs which incorporate immunotherapeutic sequences into the virus genome. This work focuses on creation and characterization of a recombinant MRV, S1/HER2nhd, which encodes a truncated σ1 protein fused in frame with three human epidermal growth factor receptor 2 (HER2) peptides (E75, AE36, and GP2) known to induce HER2 specific CD8

Indexed as

NeoplasmsOrthoreovirus, MammalianAnimalsErb-b2 Receptor Tyrosine KinasesHumansMammalsPeptidesRecombinant Fusion ProteinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPeptidesRecombinant Fusion ProteinsBreast cancerCancer vaccineHER2Mammalian orthoreovirusOncolytic virus

Identifiers

PMID37634292
PMCPMC10592078
OpenAlexW4385998698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.